Key facts
- Core Biomedicine’s last known valuation is $33.9M (Sep 2025).
- It has raised $9.9M; the latest was Early Stage VC ($9.9M) in Sep 2025.
- Notable investors include Harvard Innovation Launch Lab, UTokyo Innovation Platform Company, Vision Incubate.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Core Biomedicine
- ·The full record, as it builds
Funding rounds
No funding rounds for Core Biomedicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Core Biomedicine
Developer of therapeutic biotechnology approaches designed for the treatment of luminal cancers. The company's platform applies advanced molecular approaches and a targeted development pipeline for conditions such as bladder, pancreatic, stomach, and colorectal cancers, enabling the healthcare sector to expand treatment options and improve clinical outcomes for patients with high unmet medical needs.
- Sector
- Healthcare
- HQ
- Allston, MA, United States
- Founded
- 2022
- Website
- corebiomedicine.com/
- Ownership
- Privately Held (backing)
Core Biomedicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Core Biomedicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Core Biomedicine in its N-PORT filings yet. We sweep new filings monthly.